Autopsy report · NCT06359379

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

“Terminated due to the sponsor's decision.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 1 year 3 months before it stopped.
• 30 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Shuttle Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Glioblastoma, IDH-wildtype

Interventions

Ropidoxuridine

Participants

30

Sites

6

Countries

United States

Trials that died the same way

• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
  “Terminated by sponsor” (93% match in meaning)
• Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache
  “Terminated at the request of the financial sponsor.” (92% match in meaning)
• Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
  “Terminated by previous Sponsor decision” (89% match in meaning)
• RibFix Advantage™ Post-Market Follow-Up
  “Sponsor Terminated” (89% match in meaning)
• ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
  “Terminated - Sponsor Decision” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.